Showing 2623 results
- https://www.novartis.com/news/media-releases/novartis-announces-completion-transactions-gskCompletes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus…
- https://www.novartis.com/news/novartis-statement-about-entresto-sacubitrilvalsartan-selection-medicare-drug-price-negotiation-program
- https://www.novartis.com/news/media-releases/novartis-gibt-abschluss-von-transaktionen-mit-gsk-bekanntMit GSK abgeschlossene Transaktionen: Übernahme des Onkologie-Portfolios von GSK, Schaffung eines Joint Venture für Consumer Healthcare und Veräusserung des Bereichs Vaccines (ohne Grippeimpfstoffe…
- https://www.novartis.com/news/media-releases/novartis-annonce-la-conclusion-des-transactions-avec-gskConclusion des transactions avec GSK incluant : l'acquisition du portefeuille oncologie de GSK, la création d'une coentreprise de Consumer Healthcare et la cession de l'activité vaccins (hors…
- https://www.novartis.com/news/media-releases/positive-phase-ii-data-highlights-benefits-alcons-rth258-patients-neovascular-wet-age-related-macular-degenerationPhase II study met primary endpoint, demonstrating promising visual acuity gains in patients with neovascular (wet) age-related macular degeneration Data shows the potential for less…
- https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-novartis-board-directorsShareholders approve 18th consecutive dividend increase to CHF 2.60 (+6%) per share for 2014 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well…
- https://www.novartis.com/news/media-releases/novartis-cdk46-inhibitor-lee011-ribociclib-receives-fda-breakthrough-therapy-designation-first-line-treatment-hrher2-advanced-breast-cancerDesignation underscores the continuing unmet need of the HR+/HER2- advanced breast cancer population and the potential of LEE011 (ribociclib) as an effective new treatment option Results…
- https://www.novartis.com/news/media-releases/alcon-achieves-us-approval-cypass-micro-stent-micro-invasive-surgical-device-treat-glaucomaUS Food and Drug Administration (FDA) grants approval for CyPass Micro-Stent for sale in the US, expanding Alcon's surgical presence to treat glaucoma The CyPass Micro-Stent is designed to…
- https://www.novartis.com/news/media-releases/novartis-delivered-solid-q2-despite-full-quarter-us-gleevec-generic-impact-significant-positive-innovation-news-strengthens-future-growth-prospectsQ2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosentyx (…
- https://www.novartis.com/news/media-releases/novartis-appoints-patrick-horber-md-president-international-marie-france-tschudin-president-innovative-medicines-international-and-chief-commercial-officer-steps-down-from-executive-committee-novartisAfter nearly seven years at Novartis and more than four years as a member of the ECN, Ms. Tschudin will pursue her next chapter of leadership outside of Novartis Dr. Horber to drive next phase…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 263
- › Next page